P. Vural, S. De?irmencio?lu, H. Parildar-Karpuzo?lu, et al., “The Combinations of TNF Alpha-308 and IL-6-174 or IL-10-1082 Genes Polymorphisms Suggest an Association with Susceptibility to Sporadic Late-Onset Alzheimer’s Disease,” Acta Neurological Scandinavica, Vol. 120, No. 6, 2009, pp. 396-401.
doi:10.1111/j.1600-0404.2009.01230.x
-
TITLE:
Ratanasampil (Tibetan Medicine, RNSP) Reduces β-Amyloid Protein (Aβ) and Pro-Inflammatory Factor Levels and Improves Cognitive Functions in Mild-to-Moderate Alzheimer’s Disease (AD) Patients Living at High Altitude
AUTHORS:
Aiqin Zhu, Aiqi Xi, Guofeng Li, Yinglan Li, Baoxia Liao, Xing Zhong, Jingping Zhou, Sonqin Gu, Meihua Yu, Yide Chu
KEYWORDS:
Ratanasampil (RNSP, Tibetan Medicine); Alzheimer’s Disease; β-Amyloid Peptide; Aβ42/Aβ40 Ratio; Pro-Inflammatory Factors; Cognitive Function
JOURNAL NAME:
Journal of Behavioral and Brain Science,
Vol.2 No.1,
February
29,
2012
ABSTRACT: Ratanasampil (RNSP) is a traditional Tibetan medicine used for the treatment of stroke and cerebrovascular diseases. Previous discoveries that RNSP can reduce β-amyloid protein levels and increase learning and memory in Alzheimer’s mouse models (Tg2576) led us to investigate whether RNSP can improve cognitive functions in Alzheimer’s patients. In this study, 146 AD patients living in Qinghai province received either one gram or 0.33 gram daily of RNSP for 16 weeks. Placebo patients received Piracetam. Serum Aβ40 and Aβ42 levels were measured at the beginning of the study and after 4 and 16 weeks of treatment. Compared to the same group before treatment, MMSE scores, ADAS-cog scores and ADL scores were significantly improved (p 0.05, p > 0.05). After 16-week treatment, serum TNF-α, IL-1β, IL-6 and Aβ42 levels were significantly decreased (p
Related Articles:
Early onset versus late onset in Alzheimer’s disease: What is the reliable cut-off?
Gianfranco Spalletta, Vincenzo De Luca, Alessandro Padovani, Luca Rozzini, Roberta Perri, Amalia Bruni, Vincenzo Canonico, Alberto Trequattrini, Giuseppe Bellelli, Carla Pettenati, Floriana Pazzelli, Carlo Caltagirone, Maria Donata Orfei
DOI:
10.4236/aad.2013.21005
5,253 Downloads 10,241 Views Citations
Pub. Date:
March
12,
2013
FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer’s Disease
John Murray, Wai H. Tsui, Yi Li, Pauline McHugh, Schantel Williams, Megan Cummings, Elizabeth Pirraglia, Lilja Solnes, Ricardo Osorio, Lidia Glodzik, Shankar Vallabhajosula, Alexander Drzezga, Satoshi Minoshima, Mony J. de Leon, Lisa Mosconi
DOI:
10.4236/ami.2014.42003
5,047 Downloads 7,178 Views Citations
Pub. Date:
April
16,
2014
PKR and PP1C Polymorphisms in Alzheimer’s Disease Risk
Ernest Palomer, Gerard ILL-Raga, Marta Tajes, Eva Ramos-Fernández, Mònica Bosch-Morató, Biuse Guivernau, José J. Galán, Jordi Clarimón, Carmen Antúnez, Mercé Boada, Luis M. Real, César Fandos, Francisco J. Muñoz
DOI:
10.4236/nm.2011.23031
4,492 Downloads 8,256 Views Citations
Pub. Date:
September
28,
2011
